Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies, a biopharmaceutical company, has reported positive results of Phase 3 trial (HBV-16), demonstrating the superiority of Heplisav over Engerix-B in diabetic subset population.
Subscribe to our email newsletter
Heplisav when given as 2 doses over 4 weeks in modified intent to treat (MITT) analysis of adults with type II diabetes protected a greater proportion of subjects as compared to Engerix-B given as 3 doses over 24 weeks.
The MITT subpopulations comprised all diabetic subjects who had received at least one dose of any of the four Heplisav or Engerix-B and had at least one post vaccination immunogenicity result.
Dynavax president and chief medical officer Tyler Martin said the results showed the superiority of Heplisav in diabetics and confirmed their retrospective analysis reported last year.
"In light of the current public health discussions regarding HBV protection of this susceptible population, these results have important medical significance," Martin added.
The company will present additional data for the diabetic subset population at the Infectious Diseases Society of America (IDSA) on 21 October.